CytomX Therapeutics website screenshot

CytomX Therapeutics

CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company based in South San Francisco, California, pioneering a novel class of masked, conditionally activated biologic therapeutics built on its proprietary Probody platform. The Probody technology is engineered to remain inactive in healthy tissue and to become selectively unmasked and activated within the tumor microenvironment, with the goal of producing more potent, less toxic cancer medicines. The company's pipeline spans antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies, and immunotherapies, advanced both internally and through partnerships with major pharmaceutical companies. CytomX is a publicly traded company (Nasdaq CTMX). This API Evangelist profile was surfaced as a portfolio company of Canaan Partners; as a biopharmaceutical research organization CytomX does not publish a public developer API, so this profile carries company identity and domain-security posture rather than API artifacts.

CytomX Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Cancer Therapeutics.

CytomX Therapeutics’ developer surface includes engineering blog, support, and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotechnologyPharmaceuticalsOncologyCancer TherapeuticsClinical StageLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.8/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 1.3 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/cytomx: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Cytomx Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 3

The organization behind the API

Website
Website
 Blog
Blog
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: cytomx
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/cytomx.png
name: CytomX Therapeutics
description: CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company based in South San Francisco,
  California, pioneering a novel class of masked, conditionally activated biologic therapeutics built on its proprietary Probody
  platform. The Probody technology is engineered to remain inactive in healthy tissue and to become selectively unmasked and
  activated within the tumor microenvironment, with the goal of producing more potent, less toxic cancer medicines. The company's
  pipeline spans antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies, and immunotherapies, advanced both
  internally and through partnerships with major pharmaceutical companies. CytomX is a publicly traded company (Nasdaq CTMX).
  This API Evangelist profile was surfaced as a portfolio company of Canaan Partners; as a biopharmaceutical research organization
  CytomX does not publish a public developer API, so this profile carries company identity and domain-security posture rather
  than API artifacts.
url: https://raw.githubusercontent.com/api-evangelist/cytomx/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-industry: biopharmaceutical
x-ticker: CTMX
x-headquarters: South San Francisco, California, USA
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Cancer Therapeutics
- Clinical Stage
- Life Sciences
apis: []
common:
- type: DomainSecurity
  url: security/cytomx-domain-security.yml
- type: Website
  url: https://cytomx.com
- type: Blog
  url: https://ir.cytomx.com/news-releases
- type: Support
  url: https://cytomx.com/contact/
- type: LinkedIn
  url: https://www.linkedin.com/company/cytomx-therapeutics
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence